Results 121 to 130 of about 1,845,186 (297)
Prompt injection in manuscripts: exploiting loopholes or crossing ethical lines? [PDF]
Res Integr Peer RevTang S, Li Z.
europepmc +1 more source
Tumor mutational burden as a determinant of metastatic dissemination patterns
Molecular Oncology, EarlyView.This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal +4 more
wiley +1 more source
Desk Rejection Decisions - Do Co-Editors-In-Chief of This Journal Agree? [PDF]
Int J Public HealthKünzli N +4 more
europepmc +1 more source
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
Symbolic scarcity and epistemic waste: a systems theory of academic publishing failure. [PDF]
Res Integr Peer RevHansen T.
europepmc +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
The role of society journals in protecting the scientific record. [PDF]
Mol Biol EvolRusso CAM, Gaut BS.
europepmc +1 more source